CGT
MRNS

Capital Guardian Trust’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Capital Guardian Trust’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,030
Closed -$7K – 576
2017
Q1 		$7K Hold
1,030
– – ﹤0.01% 567
2016
Q4 		$4K Hold
1,030
– – ﹤0.01% 638
2016
Q3 		$7K Hold
1,030
– – ﹤0.01% 614
2016
Q2 		$5K Hold
1,030
– – ﹤0.01% 615
2016
Q1 		$22K Hold
1,030
– – ﹤0.01% 507
2015
Q4 		$31K Hold
1,030
– – ﹤0.01% 491
2015
Q3 		$34K Hold
1,030
– – ﹤0.01% 469
2015
Q2 		$48K Hold
1,030
– – ﹤0.01% 447
2015
Q1 		$37K Buy
+1,030
New +$45.2K ﹤0.01% 471

Other funds holding MRNS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Guardian Trust's MRNS Position: Q2 2017 in Review

Capital Guardian Trust sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2017, closing a stake of 1,030 shares — an estimated $7K sold.

Capital Guardian Trust first reported a position in MRNS in Q1 2015 and held it in 9 quarters. The position peaked at $48K in Q2 2015. 24 funds tracked by Wall St. Rank hold MRNS as of Q2 2017.

  • Capital Guardian Trust reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Capital Guardian Trust sold 1,030 Marinus Pharmaceuticals, Inc shares in Q2 2017, an estimated $7K.
  • Capital Guardian Trust first reported a position in Marinus Pharmaceuticals, Inc in Q1 2015 and held it in 9 quarters.
  • Capital Guardian Trust's Marinus Pharmaceuticals, Inc position peaked at $48K in Q2 2015.
  • 24 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2017.

Based on Capital Guardian Trust's 13F filing for Q2 2017, filed 14 Aug 2017.